Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Akso Health Group ADR (AHG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AHG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.81% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 479.35M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.67 | 52 Weeks Range 0.74 - 1.98 | Updated Date 06/29/2025 |
52 Weeks Range 0.74 - 1.98 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.08 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -77.92% | Operating Margin (TTM) -7.8% |
Management Effectiveness
Return on Assets (TTM) -3.73% | Return on Equity (TTM) -6.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 395956654 | Price to Sales(TTM) 56.7 |
Enterprise Value 395956654 | Price to Sales(TTM) 56.7 | ||
Enterprise Value to Revenue 46.83 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 396160992 | Shares Floating 714403226 |
Shares Outstanding 396160992 | Shares Floating 714403226 | ||
Percent Insiders - | Percent Institutions 0.07 |
Upturn AI SWOT
Akso Health Group ADR
Company Overview
History and Background
Akso Health Group ADR, originally known as China Commercial Credit, underwent a significant business transformation in 2020, shifting its focus to providing online and offline healthcare products and services. Founded in 2006, the company initially operated in the financial services sector before pivoting to the healthcare industry.
Core Business Areas
- Online Pharmacy: Akso operates an online pharmacy platform that sells prescription and over-the-counter medications, health supplements, and medical devices.
- Telemedicine Services: Akso offers telemedicine consultations, enabling patients to connect with healthcare professionals remotely for diagnosis and treatment.
- Health Management Solutions: Akso provides health management services, including personalized health plans, chronic disease management programs, and health data analysis.
- Offline Retail Pharmacy: Akso also operates a chain of retail pharmacies across China.
Leadership and Structure
The leadership team includes Ruilin Cai (CEO). Organizational structure is not readily available to the public as of October 26, 2023
Top Products and Market Share
Key Offerings
- Prescription Medications: Akso sells a wide range of prescription medications through its online pharmacy. Market share information is not specifically available, but the online pharmacy market in China is highly competitive. Competitors include Alibaba Health(9618.HK) and JD Health(6618.HK).
- Over-the-Counter Medications: Akso offers various over-the-counter medications for common ailments. The OTC market is also very competitive.Competitors include Alibaba Health(9618.HK) and JD Health(6618.HK).
- Health Supplements: Akso sells a range of health supplements aimed at improving overall wellness. Competitors include Alibaba Health(9618.HK) and JD Health(6618.HK).
Market Dynamics
Industry Overview
The Chinese healthcare market is experiencing rapid growth, driven by an aging population, increasing disposable incomes, and growing health awareness. E-commerce and telemedicine are becoming increasingly prevalent.
Positioning
Akso is positioned as a provider of online and offline healthcare products and services, targeting consumers seeking convenience and accessibility. Competitive advantages may stem from its integrated platform and focus on specific health needs.
Total Addressable Market (TAM)
The Chinese healthcare market TAM is estimated to be in the trillions of USD, with significant potential for growth in the online pharmacy and telemedicine segments. Akso is positioned to capture a portion of this market through its digital platform.
Upturn SWOT Analysis
Strengths
- Online and Offline Integration
- Telemedicine Services
- Health Management Solutions
- Established Pharmacy Network
Weaknesses
- Relatively Small Market Share
- Limited Brand Recognition Compared to Larger Competitors
- Dependence on Regulatory Approvals
- Volatility of ADR stocks
Opportunities
- Growing Demand for Online Healthcare Services
- Expanding Telemedicine Adoption
- Partnerships with Healthcare Providers
- Government Support for Healthcare Innovation
Threats
- Intense Competition from Established Players
- Changing Regulatory Landscape
- Price Wars
- Data Security Risks
Competitors and Market Share
Key Competitors
- JD Health (9618.HK)
- Alibaba Health (6618.HK)
- Ping An Healthcare and Technology Company Limited (1833.HK)
Competitive Landscape
Akso faces intense competition from larger, more established players with greater resources and brand recognition. Akso must differentiate itself through superior service, niche offerings, or strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the business model transformation and competitive landscape.
Future Projections: Future growth projections are subject to significant uncertainty and depend on Akso's ability to execute its strategy and navigate the competitive landscape.
Recent Initiatives: Akso's recent initiatives likely involve expanding its online platform, forging partnerships, and introducing new healthcare services.
Summary
Akso Health Group ADR is a small player in a very competitive Chinese online healthcare market. Its business model is sound but its ability to compete depends on executing its strategy effectively. Its small market share creates concerns about long-term viability and its ADR status adds further volatility. Its dependence on regulatory changes and approvals is another risk it needs to overcome to be successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Websites
- Financial News Outlets
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akso Health Group ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2006-12-28 | CEO & Chairwoman of the Board Ms. Yilin Wang | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 9 | Website https://www.ahgtop.com |
Full time employees 9 | Website https://www.ahgtop.com | ||
Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People's Republic of China. It operates Xiaobai Maimai App that offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, and cost-saving promotions at petrol gas stations. The company also sells medical devices, such as defibrillators and anesthesia laryngoscope. In addition, it is involved in the provision of health treatment services. The company was formerly known as Xiaobai Maimai Inc. and changed its name to Akso Health Group in December 2021. Akso Health Group was founded in 2014 and is headquartered in Qingdao, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.